<DOC>
	<DOCNO>NCT01847235</DOCNO>
	<brief_summary>The purpose study determine efficacy safety temozolomide patient relapse advanced anaplastic oligodendroglioma anaplastic oligoastrocytoma .</brief_summary>
	<brief_title>Temozolomide Relapsed Advanced Anaplastic Oligodendroglioma Oligoastrocytoma : Single-arm , Phase II Trial</brief_title>
	<detailed_description>Patient relapse advanced anaplastic oligodendroglioma anaplastic oligoastrocytoma enrol . Enrolled patient begin temozolomide 200 mg/m2/d fast state 5 consecutive day ( 1,000 mg/m2 per 28-day cycle ) . Patients previously treat chemotherapy initially receive temozolomide 150 mg/m2/d 5 day ( 750 mg/m2 per cycle ) .Patients receving total 6 cycle chemotheray ( 4weeks/cycle * 6cycles = 24weeks ) . If patient show response Temozolomide , treatment continue investigator 's discretion . During administration Temozolomide , vital sign , physical examination , ECOG performance status , height , weight , hematology chemistry test , adverse event concomitant drug evaluate every four week . Brain MRI tumor assessment perform every 12 week .</detailed_description>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically prove anaplastic oligodendroglioma oligoastrocytoma Progressed relapse surgery radiation therapy Female male age 20 year At least 1 measurable mass lesion ECOG performance status 03 Adequate organ function absolute neutrophil count &gt; 1,500/μL platelet count &gt; 75,000/μL hemoglobin great 9 g/dL 900g/L serum creatinine less 1.5 time upper limit laboratory normal total serum bilirubin le 1.5 time upper limit laboratory normal AST ALT less three time upper limit laboratory normal Prior course temozolomide Combined glioblastoma Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Temozolomide</keyword>
</DOC>